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Abstract 
PTEN is one of the most frequently mutated genes in human cancers. The frequency of 
PTEN alterations is particularly high in endometrial carcinomas. Loss of PTEN leads to a 
dysregulation of cell division and promotes the accumulation of cell cycle complexes such 
as Cyclin D1-CDK4/6, which is an important feature of the tumoral phenotype. Cell cycle 
proteins have been presented as key targets in the treatment of the pathogenesis of cancer, 
and several CDK inhibitors have been developed as a strategy to generate new anticancer 
drugs. Palbociclib (PD-332991) specifically inhibits CDK4/6 and it has been approved for 
its use in metastatic breast cancer in combination with letrazole. Here, we have used a 
tamoxifen-inducible PTEN knock-out mouse model to assess the anti-tumoral effects of 
Cyclin D1 knock-out and CDK4/6 inhibition by Palbociclib on endometrial tumors. 
Interestingly, both Cyclin D1 deficiency and Palbociclib treatment trigger shrinkage of 
endometrial neoplasias. In addition, Palbociclib treatment significantly increases PTEN 
deficient mice survival and, as expected, has a general effect reducing tumor-cell 
proliferation. To further analyze the effects of Palbociclib on endometrial carcinoma, we 
have established subcutaneous tumors with human endometrial cancer cell lines and 
primary endometrial cancer xenografts, which allow us to provide more translational and 
predictive data. To date, this is the first pre-clinical study evaluating the response to 
CDK4/6 inhibition in endometrial malignancies driven by PTEN deficiency, unveiling an 
important role of the Cyclin D-CDK4/6 activity in their development.  
Keywords: PTEN, endometrial carcinoma, Cyclin D1, CDK4/6, Palbociclib  
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Introduction 
Activation of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) promotes cell 
survival and proliferation. The most important negative regulator of this pathway is PTEN 
(phosphatase and tensin homolog deleted on chromosome 10), which antagonizes the PI3K 
activity by dephosphorylating phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to 
phosphatidylinositol (4,5)-bisphosphate (PIP2)[1,2].  
PTEN is one of the most frequently mutated genes in human cancers[3]. The frequency of 
PTEN alterations is particularly high in endometrial carcinomas (EC), which are the most 
common tumors of the female genital tract[4]. Nearly 70% of endometrial tumors present 
PTEN alterations[5]. 
The role of PTEN in carcinogenesis has been validated by different knock-out mouse 
models[6-8]. Recently, our group has generated a tamoxifen-inducible PTEN knock-out 
mouse model. Loss of PTEN leads to extremely rapid and efficient development of 
endometrial hyperplasias and in situ carcinomas, prostate neoplasias and thyroid 
hyperplasias[9].  
It is well-known that absence of PTEN triggers an abnormal cell division and alters the 
expression of cell cycle regulators such as Cyclin D1[9]. The Cyclin D-CDK4/6 signaling 
axis is important for cell division and tumor growth[10,11]. The D-type Cyclin family is 
composed by three different proteins (D1, D2 and D3) and its expression is induced upon 
cell exposure to mitogens. Therefore, D-type Cyclins link cell environment to machinery 
that drives cell cycle progression[12,13]. Overexpression of the D-type Cyclins and/or 
CDK4/6 proteins is commonly seen in a number of human tumors. Cyclin D1 is 
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overexpressed in numerous neoplasms of prostate and endometrium[10,14-16]. In breast 
cancer, overexpression reaches approximately 50% of the cases[17].  
CDK inhibiton has been presented as a strategy to generate new anticancer drugs. The 
effectiveness of CDK4 and CDK6 inhibition in cancer is being assessed with highly 
selective inhibitors, such as Palbociclib[10,18,19], which specifically inhibits CDK4/6, but 
not the other CDKs[20].  
Here, we have first studied PTEN-driven tumorigenesis in the context of Cyclin D1 
deficiency. Next, we have used a tamoxifen-inducible PTEN knock-out mouse model and 
different approaches with human endometrial cancer cell lines to assess the anti-tumoral 
effects of Palbociclib. Finally, we have also performed primary endometrial cancer 
xenografts to provide more translational research data. Our results demonstrate that 
Palbociclib treatment triggers shrinkage of endometrial lesions and reduces tumor cell 
proliferation. To date, this is the first pre-clinical study evaluating the response to 
Palbociclib in endometrial malignancies driven by PTEN deficiency.  
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Materials and methods 
Cell lines and culture conditions 
Endometrial carcinoma cell lines were grown in two dimensions and in three-dimensional 
(3D) cultures as previously described[21,22]  
Cell viability and cell cycle distribution analysis 
Cell viability and cell cycle distribution was evaluated as previously described[21,23].  
Isolation of endometrial epithelial cells and establishment of 3D cultures 
Isolation of mouse endometrial epithelial cells and establishment of 3D cultures were 
performed as previously described[24].  
When required, PTEN deletion in endometrial cells isolated from Cre:ERT+/-PTENfl/fl mice 
was induced by addition of 0.5 µg/ml of tamoxifen in culture medium.  
Bromodeoxyuridine Incorporation 
The bromodeoxyuridine protocol was performed as previously described[24].  
Confocal Imaging and Spheroid Diameter Evaluation 
Images of endometrial epithelial spheroids were captured and digitized as previously 
described[25]. Epithelial glands diameter analysis was processed by image analysis 
software (ImageJ version 1.46r; NIH, Bethesda, MD).  
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RNA extraction, Reverse transcriptase-polymerase chain reaction (RT-PCR) and 
quantitative real-time PCR (RT-qPCR) 
 
Total RNA was extracted following manufacturer’s instructions (RNeasy Total RNA kit; 
Qiagen, Valencia, CA, USA). RNA was retrotranscribed to cDNA using the High Capacity 
cDNA Archive Kit (Applied Biosystems, Foster City, USA). The cDNA product was used 
as a template for subsequent PCR. 
Relative mRNA expression levels were calculated using the 2ΔΔCt method and Ct values 
were normalized to the housekeeping gene β-Glucuronidase (GusB). Taqman® technology 
from Applied Biosystems was used for real-time RT-qPCR analyses. Probes used are 
detailed in supplementary table 1 (Supporting Information).  
Animals 
Mice were maintained as previously described[23]. The in vivo studies complied with Law 
5/1995 and Act 214/1997 of the Autonomous Community (Generalitat de Catalunya) and 
EU Directive EEC 63/2010, and were approved by the Ethics Committee on Animal 
Experiments of the University of Lleida and the Ethics Commission in Animal 
Experimentation of the Generalitat de Catalunya. 
Cre:ERT+/− PTENf/f mice were generated as previously described[9]. Cyclin D1 (referred 
here as CycD1) knock-out mice were obtained from the Jackson Laboratory (Bar Harbor, 
ME). Cre:ERT+/− PTENf/f CycD1-/- mice were bred by crossing Cre:ERT+/− PTENf/f and 
CycD1-/- mice (Sup.Fig.1A).  
Immunodeficient SCID mice were maintained in Specific Pathogen Free (SPF) conditions. 
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Tamoxifen  
Tamoxifen was dissolved and administered as previously described[9].   
Palbociclib  
Palbociclib was obtained from Pfizer Inc. Palbociclib powder was stored at room 
temperature and protected from light.  
For in vitro experiments, a 2.5 mM stock of Palbociclib was prepared in DMSO and stored 
as single use aliquots at -80ºC.   
For in vivo experiments, Palbociclib was dissolved in Sodium L-Lactate (Sigma-Aldrich; 
St. Louis, MO) buffer (50mM, pH 4.0). Cre:ERT+/− PTENf/f mice were given a single daily 
dose of 100 mg/kg of Palbociclib by oral gavage, starting two weeks after tamoxifen 
injection. For Palbociclib acute treatment, Cre-ERT+/- PTENfl/fl animals were treated for 
three consecutive days with 75, 100 or 150 mg/kg of the inhibitor. For survival 
experiments, mice received 5 doses per week until the moment of sacrifice. In each 
experiment, control animals were given vehicle following the same schemes. 
Subcutaneous xenografts and treatment  
Subcutaneous HEC-1A or MFE-296 cells-derived tumors were developed, maintained and 
measured as previously described[21]. When tumors reached 100 mm3, mice were treated 
by oral gavage with vehicle or 150 mg/kg Palbociclib for 15 days.  
Patient-derived tumor xenograft (PDX) establishment and treatment 
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All animal procedures were performed according to protocols approved by the Animal 
Experimentation Ethics Committee from the Vall Hebron University Hospital.  
A patient-derived tumor xenograft (PDX), PDX741, was generated using fresh primary 
tumor tissue from an endometrioid endometrial cancer patient by subcutaneously 
implantation in the animal flanks. For evaluation of drug efficacy, small pieces of PDXs 
were surgically transplanted subcutaneously into female Swiss nude mice, 6 week old, and 
allowed to establish. When the tumors reached approximately 200 mm3, mice were 
randomized into groups of 4-5 mice and treated with vehicle or Palbociclib (150 mg/kg).  
Mice were treated daily by oral gavage for ten days. Tumors were measured twice weekly 
with a vernier caliper, and volumes were calculated as (length×width2)/2=mm3. 
Histopathology and Immunohistochemistry 
Histopathological and immunohistochemical studies were performed as previously 
described[23]. The antibodies used are detailed in supplementary table 2 (Supporting 
Information). 
Immunohistochemical results were graded by considering the intensity of the staining. A 
histological score was obtained by using an automated imaging system, the ACIS® III 
Instrument (Dako). An intensity score was obtained from 4 different areas of each sample. 
Proliferation analysis 
Proliferation from Ki-67 and Cyclin D1 immunohistochemistries was calculated as 
previously described[9]. 
Western Blot  
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Western Blot was performed as previously described[23]. The antibodies used are detailed 
in Table 2 (Supporting Information).  
Statistical analysis  
All the experiments were performed at least three times. N indicates the number of mice. 
Statistical analyses were performed with GraphPad Prism 6.0 software. Values are 
presented as means ± standard errors of the mean (s.e.m). Data were compared using 
Student’s t-test, one-way ANOVA or two-way ANOVA, with p < 0.05 considered as 
significant. Chi square test was used to compare the incidence of histopathological lesions 
between groups. Mantel-Cox test, followed by the Gehan-Breslow-Wilcoxon test, was used 
to compare mice survival between groups. 
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Results 
PTEN deletion enhances Cyclin D1 expression. 
Previous studies demonstrate that PTEN protein influences Cyclin D1 expression, but the 
reported results are still controversial[26-28]. To address this issue, we used a tamoxifen-
inducible PTEN knock-out mice[9], which rapidly develop endometrial intraepithelial 
neoplasias (EIN), thyroid hyperplasias and prostatic intraepithelial neoplasias (PIN) 
between 6-8 weeks after tamoxifen-induced PTEN deletion (Sup.Fig.2A, B and C). 
By immunohistochemical analysis, we observed an increment of Cyclin D1 after PTEN 
loss in endometrium, thyroid and prostate (Sup.Fig.2A, B and C), and this observation was 
concomitant with Ki-67 increased expression (Sup.Fig.2G). Moreover, Cyclin D1 
expression was incremented on lysates from endometrial epithelial 3D cultures, and thyroid 
or prostate tissues (Sup.Fig.2D, E and F). Collectively, these results indicate that PTEN 
loss increases Cyclin D1 expression. 
Effects of Cyclin D1 deficiency in PTEN-driven neoplasias. 
Having demonstrated that PTEN deficiency correlated with an increment of Cyclin D1, we 
questioned whether such increase was required to drive PTEN-loss induced tumorigenesis. 
We generated Cre:ERT+/- PTENfl/fl CycD1-/- mice to achieve simultaneous loss of PTEN and 
Cyclin D1 (Sup.Fig.1A). The phenotype of mice lacking Cyclin D1 compromised the 
viability of Cre:ERT+/- PTENfl/fl CycD1-/- mice, which limited the number of animals used in 
the study[29,30].  
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The experimental workflow is shown in figure 1A and supplementary figures 3A and 4A. 
Interestingly, Cyclin D1 absence led to a reduction in the incidence and progression of 
endometrial lesions (Fig.1B). The majority of histological changes found in the 
endometrium of the Cre:ERT+/- PTENfl/fl CycD1-/- were classed as hyperplasias, and only a 
17% of the animals progressed to EIN, whereas EIN incidence in the wild-type counterparts 
was near to 53%. Macroscopic analysis revealed no reduction in thyroid (Sup.Fig.3B) and 
prostate (Sup.Fig.4B) size of Cre:ERT+/- PTENfl/fl CycD1-/- mice. Furthermore, histological 
examination revealed that Cyclin D1 deficiency did not impair PTEN tumorigenesis neither 
in thyroid nor in prostate (Sup.Fig.3C and Sup.Fig.4C). 
By Ki-67 immunohistochemistry, we found that endometrium, thyroid and prostate from 
animals of both genotypes showed the same proliferating rate (Fig.1C, Sup.Fig.3D and 
Sup.Fig.4D, respectively). Finally, we analyzed the expression of several components of 
the cell cycle in all three tissues from Cre:ERT+/- PTENfl/fl CycD1+/+ and Cre:ERT+/- PTENfl/fl 
CycD1-/- mice. As depicted in figure 1D and supplementary figures 3E and 4E, absence of 
Cyclin D1 did not modify the expression of any of the elements analyzed.  
Finally, we also analyzed the phosphorylation status of Rb as a biomarker of Cyclin D-
CDK4/6 activity. The immunohistochemistry against p-Rb (Ser780), which is specifically 
phosphorylated by CDK4/6, revealed no blockade of the Cyclin D-CDK4/6 axis in the 
context of Cyclin D1 absence (Fig.1E, Sup.Fig.3F and Sup.Fig.4F). These results strongly 
support the hypothesis that proliferation of PTEN deficient malignancies is not dependent 
on Cyclin D1. 
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CDK4/6 inhibition triggers an anti-proliferative effect on mouse PTEN deficient 
endometrial cells in vitro. 
In an attempt to understand the molecular basis of the Cyclin D1-independent proliferation 
and cell cycle progression in PTEN deficient tumors, we hypothesized that compensatory 
expression of other Cyclins may override the loss of Cyclin D1. We determined the levels 
of all three D-type Cyclins by RT-qPCR from PTEN proficient and PTEN deficient 
epithelial endometrial 3D cultures. As depicted in supplementary figure 5A, PTEN ablation 
not only induced an up-regulation of Cyclin D1 mRNA expression, but also of Cyclin D2 
and Cyclin D3.  
It seems that loss of PTEN enhances the expression of all the D-type Cyclins, making the 
absence of a single Cyclin D insufficient to impede the Cyclin D-CDK4/6 axis. For that 
reason, we evaluated the impact of specific CDK4/6 inhibition on cell proliferation to 
effectively block Cyclin D-CDK4/6 axis. For this purpose, we established endometrial 3D 
cultures from Cre:ERT+/- PTENfl/fl mice treated (PTEN KO) or not (PTEN WT) with 
tamoxifen to induce PTEN excision. 3D cultures were exposed to Palbociclib for 48 hours. 
Palbociclib treatment resulted in a significant decrease of glandular size (Sup.Fig.5B) and 
BrdU-incorporating cells (Sup.Fig.5C). All the above results demonstrate that CDK4/6 
inhibition by Palbociclib induces a decrease of endometrial cells proliferation in vitro.  
Palbociclib treatment reduces PTEN-induced endometrial carcinoma in vivo. 
Next, we sought to investigate whether the inhibitor was equally effective in vivo in our 
tamoxifen-inducible PTEN knock-out mouse model. The treatment scheme is shown in 
figure 2A. Histopathological evaluation revealed that Palbociclib treated animals presented 
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endometrial lesions of significant lesser extent than the untreated ones. Vehicle treated 
animals displayed EIN (67%) and severe hyperplasia (33%), whereas most animals 
receiving Palbociclib showed hyperplasia (40%) and severe hyperplasia (40%). Moreover, 
only 10% of the lesions progressed to EIN, and another 10% conserved normal histology 
(Fig.2B). In addition, uteri from Cre:ERT+/- PTENf/f mice treated with the inhibitor 
presented a substantial reduction of the Ki-67 proliferation marker in comparison with the 
untreated ones (Fig.2C).  
In other tissues, macroscopic analysis revealed a dramatic reduction in thyroid and prostate 
size and weight (Sup.Fig.6B and Sup.Fig.7B) from Cre:ERT+/- PTENf/f mice treated with 
Palbociclib, following the treatment schemes shown in Sup.Fig.6A and Sup.Fig.7A. 
Moreover, Ki-67 expression was also reduced in both tissues treated with the inhibitor 
(Sup.Fig.6D and Sup.Fig.7D), indicating that Palbociclib is effective at decreasing tumor 
cell proliferation both in thyroid and prostate. Surprisingly, histopathological analysis 
revealed that neither thyroid hyperplasias nor prostate neoplasias incidences were reduced 
by Palbociclib (Sup.Fig.6C and Sup.Fig.7C).  
Endometrial neoplasia response to Palbociclib correlates with Rb phosphorylation on 
Ser780 in vivo. 
We intended to investigate the underlying molecular mechanism explaining anti-tumoral 
effect of Palbociclib in vivo on endometrium. We analyzed by immunohistochemistry the 
expression of p-Rb (Ser780) in the tissues after short course and long-term treatment with 
the inhibitor. 
15 
 
The experimental workflow diagram for short-course treatment is showed in figure 3A. 
Palbociclib treatment led to a potent reduction of p-Rb (Ser780) in the endometrium, 
regardless of the dose tested (Fig.3B and Sup.Fig.8A). Surprisingly, the reduction of p-Rb 
(Ser780) levels was not observed in the endometrium after 21 days of treatment (Fig.3C 
and Sup.Fig.8B). In our hands, Palbociclib was not effective at reducing Rb 
phosphorylation neither in thyroid nor prostate (Fig.3B and 3C, Sup.Fig.8C and 8D).  
It has been suggested that in the absence of Cyclin D-CDK4/6 activity, the phosphorylation 
of p-Rb could be carried out by Cyclin E-CDK2 in a scenario with low activity of CDK 
inhibitors such as p27[12,31,32]. After long treatment with Palbociclib in the endometrium, 
our results pointed out two different situations. On the one hand, some mice displayed high 
levels of p-ERK, and this increment was concomitant with high expression of Cyclin D1, 
Cyclin E, p27 and p-Rb. On the other hand, mice presenting lower levels of p-ERK showed 
less expression of Cyclin D1, Cyclin E, p27 and p-Rb. No significant changes were 
observed on p-AKT, p-S6K and CDK2 levels (Sup.Fig.8E). Even though the presence of 
Palbociclib abrogates the Cyclin D-CDK4/6 activity, these findings lead us to hypothesize 
that D-type Cyclins present in the cells still bind to CDK inhibitors, allowing Cyclin E-
CDK2 complexes to phosphorylate p-Rb.  
Palbociclib treatment slows down endometrial tumor progression and increases 
overall mice survival.  
The therapeutical benefits of Palbociclib (administered for 21 days) on PTEN deficient 
endometrial carcinomas encouraged us to study the effects of chronic exposure to the 
inhibitor. The treatment scheme is shown in figure 4A. Chronic treatment with Palbociclib 
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induced a significant increase of mice survival. Cre:ERT+/- PTENfl/fl treated females 
presented a median survival of 47 days, whereas this value was reduced to 32 days for the 
untreated ones (Fig.4B). 
In endometrium, Palbociclib induced a delay in the development of EIN after PTEN loss. 
However, Palbociclib treated females finally displayed severe hyperplasia and EIN 
(Fig.4E). As depicted by figure 4C and 4D, macroscopic and histological analysis revealed 
no differences between PTEN deficient thyroids treated or not with the inhibitor. 
Collectively, these results suggest that Palbociclib treatment slows down tumor 
progression, allowing increased mice survival. Nevertheless, it does not cause a significant 
regression of endometrial and thyroid malignancies induced by PTEN loss.  
Palbociclib induces an anti-proliferative effect in vitro on human endometrial 
carcinoma cell lines. 
As it has been previously described, Palbociclib treatment reduces the proliferation of 
multiple human tumoral cell lines[33]. Having demonstrated the drug anti-tumoral effect in 
PTEN deficient endometrial carcinomas in mice, we aimed to determine its therapeutic 
potential in different human endometrial cancer models. We first monitored the viability of 
two EC cell lines, HEC-1A and MFE-296, after Palbociclib treatment by a MTT 
cytotoxicity assay.  Both cell lines exposed to different concentrations of Palbociclib (2.5, 5 
and 10 µM) for 48 hours presented a significant decrease in cell viability (Sup.Fig.9A). 
Next, we also observed that treatment of HEC-1A and MFE-296 cells with 5 µM and 10 
µM Palbociclib for 48 hours resulted in a G1 phase arrest, preventing cells from entering S 
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phase (Sup.Fig.9B). Finally, as shown in supplementary figure 9C, Palbociclib also 
significantly reduced glandular size of HEC-1A cells when growing in three dimensions.  
Palbociclib exhibits anti-tumor activity against human endometrial cancer. 
Given that Palbociclib showed anti-proliferative effect on endometrial carcinoma cell lines 
in vitro, we aimed to assess whether the inhibitor presents anti-tumoral activity in vivo. 
Mice bearing HEC-1A or MFE-296 subcutaneous tumors were daily treated with 
Palbociclib at a dose of 150 mg/kg for 15 days by oral gavage. Interestingly, Palbociclib 
treatment led to a significant marked reduction in tumor growth (Fig.5A and 5C) with a 
concomitant decrease in Ki-67 expression (Fig.5B and 5D) when compared to vehicle 
treated animals. Taken together, these data indicate that Palbociclib inhibits tumoral growth 
of subcutaneously injected HEC-1A and MFE-296 cell lines into SCID mice. 
In order to circumvent the limitations of conventional pre-clinical models in terms of 
translational research, we have also generated a patient-derived tumor xenograft model 
using a primary PTEN deficient endometrioid endometrial carcinoma (Fig.6A). 
Endometrial carcinoma sample was injected subcutaneously in female mice and the effects 
of Palbociclib were assessed for ten days. As depicted in figure 6B and 6C, Palbociclib 
impaired endometrial tumorigenesis by decreasing tumor growth in those mice treated with 
the drug. Furthermore, PDX treated with Palbociclib displayed a marked reduction of Ki-67 
expression when compared with the untreated ones (Fig.6D). Finally, no significant 
reduction of p-Rb levels was observed after Palbociclib treatment (Fig.6E). 
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Discussion  
In the present work, we have investigated the role of Cyclin D-CDK4/6 axis in PTEN 
deficient endometrial tumors. 
We have observed that endometrial carcinomas induced by PTEN loss show higher 
expression of Cyclin D1 than normal tissue, consistent with previous evidences[34]. 
However, the direct effect of PTEN on Cyclin D1 expression is controversial. For instance, 
it has been reported that the mutant PTEN-G129E form reduces Cyclin D1 levels in a 
breast cancer model[28]. Some endometrial carcinomas present some mutations in this 
lipid-phosphatase domain (G129D/E/R/V). It will be interesting to determine the effect of 
these PTEN mutant forms on Cyclin D1 levels. Nevertheless, our results are not 
comparable with the above mentioned, as we work with a model of PTEN loss. We have 
focused on PTEN deficient endometrial tumors, as they represent an important part of the 
total cases. Therefore, it seems that Cyclin D1 participates somehow in PTEN-driven 
endometrial malignancies, but the underlying mechanism has not been completely 
elucidated. 
Here, we have evaluated the efficacy of Palbociclib in endometrial carcinomas in PTEN 
deficient mice. Our results pointed out that Palbociclib reduces tumor cell proliferation and 
disrupts the tumorigenic process in the endometrium. Interestingly, Cyclin D1 deficiency 
alone already decreases the extent of endometrial lesions. 
Noteworthy, our results suggest that thyroid and prostate PTEN-deficient tumor 
maintenance exhibit dependence on Cyclin D-CDK4/6 axis, as Palbociclib decreases cell 
proliferation in both tissues. Consistently, Comstock and colleagues have reported anti-
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proliferative effect of Palbociclib on prostate human tumor tissues ex vivo[35]. 
Surprisingly, neither prostate nor thyroid tumorigenesis is disrupted after Palbociclib 
administration in our mouse model. However, it has been reported a functional 
collaboration between p18 and PTEN in tumor suppression[36]. In this model, Cyclin D-
CDK4/6 axis is exacerbated during development and before the appearance of tumors. In 
contrast, in our model, Palbociclib is given at the onset of malignancies. The distinct 
temporal intervention can lead to different response patterns. A raising question is why 
thyroid and prostate malignancies are dependent on Cyclin D-CDK4/6 inhibition for tumor 
maintenance but not for tumorigenesis. Such question can be explained because of Cyclin 
D-CDK4/6 axis proliferation-independent functions[37]. 
Therapeutic intervention on cell cycle has been proposed as an effective anti-tumor 
therapy[38,39]. Numerous clinical trials are ongoing to unveil the therapeutic benefit of 
Palbociclib both alone and in combinatorial approaches[38-40]. Patient-derived tumor 
xenografts represent an advanced pre-clinical model[41,42]. Here, we provide evidence that 
Palbociclib has therapeutic potential in a model of primary PTEN deficient endometrial 
carcinoma. However, Palbociclib has failed inducing tumor regression and cytotoxic 
effects. It is imperative to develop Palbociclib combinations with some cytotoxic agents. 
Some in vitro studies performed with breast cancer cell lines report antagonistic activity 
between Palbociclib and some chemotherapeutics[43,44]. Nevertheless, with proper cell 
cycle synchronization, synergistic killing effect is achieved in multiple models[45-47]. 
Noteworthy, Palbociclib is the first cell-cycle inhibitor that demonstrates broad-ranging 
efficacy in many tumor types. Therefore, it seems reasonable to consider Palbociclib 
combinations as a valuable promise[40].  
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Data from several groups have asserted that the status of p-Rb protein is critical for 
Palbociclib activity[33,35,38-40] and loss of Rb leads to drug resistance[38]. In our model, 
Palbociclib treatment only reduces p-Rb in the endometrium after acute treatment, but not 
in other tissues and longer treatments. Restoration of p-Rb levels may explain why 
Palbociclib fails to cause disease regression after long-term treatment in the endometrium. 
However, the role of Rb as a prognostic factor for Palbociclib treatment is still unclear. 
Consistent with this, we have found that PDX samples, which showed reduced proliferation 
and tumor growth after Palbociclib treatment, do not exhibit decreased expression of p-Rb 
protein.  Furthermore, it has been described that some patients, who do not present benefit 
after Palbociclib treatment, show decreased p-Rb[38,44,48]. In these cases, the presence of 
intact Rb function does not predict CDK4/6 dependence.  
During cell division, Cyclin D-CDK4/6 sequesters CDK inhibitors such as p27, liberating 
Cyclin E-CDK2 activity, which in turn, phosphorylates Rb. A similar reasoning could be 
used to explain the presence of p-Rb during Palbociclib treatment. However, after long 
treatment with Palbociclib, we have found out two possible scenarios. On the one hand, we 
have observed low levels of Cyclin D1, p27 and Cyclin E. On the other hand, after ERK 
activation, we have detected an up-regulation of the mentioned proteins, which correlates 
with an increment of p-Rb protein expression. We propose here that although Palbociclib 
inhibits Cyclin D-CDK4/6 kinase activity, Cyclin D1 still retains the ability to sequester 
p27 and relieve Cyclin E. In this way, Cyclin E expression may be enough to phosphorylate 
Rb protein when associated with CDK2[12,31,32]. Moreover, it is known that ERK 
pathway activation is necessary and sufficient to induce Cyclin D1 expression[49], so in the 
second context, the huge amount of Cyclin D1 may bypass Palbociclib inhibition and also 
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phosphorylate Rb protein. Furthermore, it would be interesting to determine the mechanism 
by which Cyclin E protein is up-regulated. Then, we hypothesize that Cyclin E may be 
responsible of Rb protein phosphorylation, during Palbociclib inhibition, as previously 
described[12]. Consistent with these findings, we have shown here that p-Rb expression is 
incremented in those mice expressing more Cyclin E. 
Hitherto, we report the first pre-clinical study where the therapeutical potential of 
Palbociclib is evaluated in endometrial malignancies driven by PTEN deficiency. Our 
results highlight the Palbociclib clinical potential as an anti-cancer drug in the 
endometrium.  
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Figure legends 
Figure 1. Cyclin D1 deficiency displays a slight reduction of endometrial lesions. A) 
Schematic diagram showing the experimental workflow. In short, mice were weaned 3 
weeks after birth. At 8-10 weeks old, mice were injected with a single dose of tamoxifen to 
achieve PTEN ablation. Mice were sacrificed 4-6 weeks later. (B) Representative images 
showing HE staining (top panels) and immunostaining against Cyclin D1 (bottom panels) 
on uteri collected from Cre:ERT-/- PTENfl/fl CycD1-/-, Cre:ERT+/- PTENfl/fl CycD1+/+ and 
Cre:ERT+/- PTENfl/fl CycD1-/- mice (10x), and evaluation of endometrial histology. No 
significant differences were observed by Chi square analysis. (C) Representative images 
and quantification of Ki-67 immunostaining. Data are from n=5 for each genotype and 
values are mean ± s.e.m.  no significant differences were observed by t-test analysis. (D) 
Evaluation of Cyclin D1, Cyclin D2, CDK4, CDK6, CDK2 and Cyclin E expression by 
western blot in uteri collected from Cre:ERT+/- PTENfl/fl CycD1+/+ (WT) and Cre:ERT+/- 
PTENfl/fl CycD1-/- (KO) mice. A representative image of n=3 biological replicates is shown 
for each genotype. Tubulin serves as loading control. Immunoreactive bands were 
quantified by densitometry analysis using ImageJ software. Relative levels values are 
expressed using tubulin as a reference. ∗∗P < 0.01, by t-test analysis. (E) Representative 
images of p-Rb (Ser780) immunostaining.  
Figure 2. Palbociclib treatment reduces endometrial carcinomas in PTEN deficient 
mice. (A) Schematic representation of the protocol used for Palbociclib administration. 
Briefly, mice were given a single daily dose of 100 mg/kg of the drug for 21 consecutive 
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days, starting two weeks after PTEN deletion. (B) Representative images of HE staining 
(10x) and evaluation of uteri lesions from Palbociclib untreated and treated animals. ∗P < 
0.05, by Chi square analysis. (C) Representative images and quantification of Ki-67 
immunostaining performed on uterus dissected from mice treated or not with the drug. Data 
are from n=5 for each genotype and values are mean ± s.e.m. ∗∗P < 0.01, by t-test analysis.  
Figure 3. Tumor responses to Palbociclib in the endometrium correlate with Rb 
phosphorylation on Ser780 in vivo. (A) Experimental workflow diagram showing the 
procedure used for Palbociclib acute treatment. Briefly, mice were treated with 75, 100 or 
150 mg/kg of Palbociclib for three consecutive days, starting two weeks after PTEN 
deletion. (B) Representative images of p-Rb immunostaining performed on uteri (upper 
panel), thyroid (central panel) and prostate (bottom panel) dissected from mice after short 
curse of Palbociclib. (C) Representative images of p-Rb immunostaining performed on 
uteri (left), thyroid (central panel) and prostate (right) dissected from mice after 21 days of 
treatment with Palbociclib. 
Figure 4. Effects of Palbociclib chronic treatment in PTEN deficient endometrial 
carcinomas and thyroid hyperplasias. (A) Schematic representation of the protocol used 
for Palbociclib administration. Briefly, mice were given a single daily dose of 100 mg/kg of 
the drug for 5 consecutive days followed by 2 days off treatment until mice required 
euthanasia, starting two weeks after PTEN deletion. (B) Kaplan-Meier survival curve. ∗∗∗P 
< 0.001, by Mantel-Cox test, followed by the Gehan-Breslow-Wilcoxon test. (C) 
Macroscopic images of thyroids from Palbociclib treated and untreated mice. (D) 
Representative images of HE staining (10x) and evaluation of thyroid lesions. No 
significant differences were observed by Chi square test. (E) Representative images of HE 
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staining (10x) and evaluation of uteri lesions from Palbociclib untreated and treated 
animals. No significant differences were observed by Chi square analysis. 
Figure 5. Palbociclib treatment reduces in vivo growth of endometrial carcinoma cell 
lines tumors. SCID mice bearing HEC-1A or MFE-296 subcutaneous tumors were treated 
daily by oral gavage with 150 mg/kg Palbociclib for 15 days. (A and C) Comparison of 
representative vehicle and Palbociclib treated HEC-1A (A) or MFE-296 (C) xenograft 
tumors, and graph of tumor growth over time. ∗∗∗P < 0.001, by two-way ANOVA, 
followed by the Bonferroni post hoc comparison test. (B and D) Representative images and 
quantification of Ki-67 immunostaining performed on HEC-1A (B) or MFE-296 (D) 
subcutaneous tumors from mice treated or not with the drug. Data are from n=4 for each 
group and values are mean ± s.e.m. ∗∗P < 0.01, by t-test analysis. 
Figure 6. CDK4/6 inhibition by Palbociclib in a PTEN deficient PDX impairs 
endometrial carcinogenesis. (A) Representative images of PTEN immunostaining 
performed on patient-derived endometrioid endometrial carcinoma. (B) Comparison of 
representative vehicle and Palbociclib treated PDX, and graph of tumor growth over time. 
∗∗P < 0.01, by two-way ANOVA, followed by the Bonferroni post hoc comparison test. 
(C) Slope of tumor growth at day 8 and 10 of treatment. ∗∗P < 0.01, by t-test analysis. (D) 
Representative images and quantification of Ki-67 immunostaining performed on PDX 
treated or not with the drug. Data are from n=3 for each group and values are mean ± s.e.m. 
∗∗∗P < 0.001, by t-test analysis. (E) Representative images of p-Rb immunostaining 
performed on PDX treated or not with Palbociclib. 
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Supplementary figure legends 
Supplementary Figure 1. Breeding scheme for the mice used in this study. 
Supplementary Figure 2. PTEN deletion causes an increase of Cyclin D1 and Ki-67 
expression.  Uteri, thyroids and prostates from Cre:ERT-/- PTENfl/fl or Cre:ERT+/- PTENfl/fl 
mice were analyzed 6-8 weeks after tamoxifen injection. (A, B and C). Representative 
images showing HE staining, Cyclin D1 immunohistochemistry and quantification on the 
endometrium (A), thyroid (B) and prostate (C) from Cre:ERT-/- PTENfl/fl and Cre:ERT+/- 
PTENfl/fl mice (10x). Data are from n=5 for each genotype and values are mean ± s.e.m. ∗P 
< 0.05 ∗∗P < 0.01, by t-test analysis (D) Evaluation of PTEN and Cyclin D1 expression by 
western blot in epithelial endometrial three-dimensional cultures. Tubulin serves as loading 
control. (E-F) Thyroid and prostate protein lysates were subjected to western blot analysis 
for Cyclin D1 expression. β-Actin serves as loading control. (G) Representative images 
showing Ki-67 immunohistochemistry on the endometrium (upper panel), thyroid (central 
panel) and prostate (bottom panel) from Cre:ERT-/- PTENfl/fl and Cre:ERT+/- PTENfl/fl mice 
(10x). 
Supplementary Figure 3.  Cyclin D1 is dispensable for PTEN driven thyroid 
hyperplasias. (A) Schematic diagram showing the experimental workflow. (B) 
Comparison of representative wild-type and CycD1-/- thyroids 4-6 weeks after PTEN 
deletion. (C) Representative images showing HE staining (top panels) and immunostaining 
against Cyclin D1 (bottom panels) on thyroids collected from Cre:ERT-/- PTENfl/fl CycD1-/-, 
Cre:ERT+/- PTENfl/fl CycD1+/+ and Cre:ERT+/- PTENfl/fl CycD1-/- mice (10x), and evaluation 
of thyroid histology. No significant differences were observed by Chi square analysis. (D) 
Representative images and quantification of Ki-67 immunostaining. Data are from n=5 for 
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each genotype and values are mean ± s.e.m. no significant differences were observed by t-
test analysis. (E) Evaluation of Cyclin D1, Cyclin D2, CDK4, CDK6, CDK2 and Cyclin E 
expression by western blot in thyroids collected from Cre:ERT+/- PTENfl/fl CycD1+/+ (WT) 
and Cre:ERT+/- PTENfl/fl CycD1-/- (KO) mice. A representative image of n=3 biological 
replicates is shown for each genotype. Tubulin serves as loading control. Immunoreactive 
bands were quantified by densitometry analysis using ImageJ software. Relative levels 
values are expressed using tubulin as a reference. ∗∗P < 0.01, by t-test analysis. (F) 
Representative images of p-Rb (Ser780) immunostaining. 
Supplementary Figure 4. Cyclin D1 is dispensable for PTEN driven prostatic 
neoplasias. (A) Schematic diagram showing the experimental workflow. (B) Comparison 
of wild-type and CycD1-/- prostates 4-6 weeks after PTEN deletion. (C) Representative 
images showing HE staining (top panels) and immunostaining against Cyclin D1 (bottom 
panels) on prostates collected from Cre:ERT-/- PTENfl/fl CycD1-/-, Cre:ERT+/- PTENfl/fl 
CycD1+/+ and Cre:ERT+/- PTENfl/fl CycD1-/- mice (10x), and evaluation of prostate 
histology. No significant differences were observed by Chi square analysis. hgPIN means 
high-grade PIN. (D) Representative images and quantification of Ki-67 immunostaining. 
Data are from n=5 for each genotype and values are mean ± s.e.m. no significant 
differences were observed by t-test analysis. (E) Evaluation of Cyclin D1, Cyclin D2, 
CDK4, CDK6, CDK2 and Cyclin E expression by western blot in prostates collected from 
Cre:ERT+/- PTENfl/fl CycD1+/+ (WT) and Cre:ERT+/- PTENfl/fl CycD1-/- (KO) mice. A 
representative image of n=3 biological replicates is shown for each genotype. Tubulin 
serves as loading control. Immunoreactive bands were quantified by densitometry analysis 
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using ImageJ software. Relative levels values are expressed using tubulin as a reference. ∗P 
< 0.05, by t-test analysis. (F) Representative images of p-Rb (Ser780) immunostaining. 
Supplementary Figure 5. Cyclin D-CDK4/6 axis inhibition by Palbociclib induces a 
decrease of cell proliferation in vitro. (A) RT-qPCR analysis of Cyclin D1, Cyclin D2 and 
Cyclin D3 mRNA expression from epithelial endometrial 3D cultures. Data are from n=4 
experimental replicates (independent mRNA preparations) and values are mean ± s.e.m. ∗P 
< 0.05, by t-test analysis. (B) Representative phase contrast images and measurement of 
glandular diameter of endometrial epithelial 3D cultures from Cre:ERT+/- PTENf/f exposed 
(PTEN KO) or not (PTEN WT) to tamoxifen to induce PTEN deletion, and treated or not 
with Palbociclib (5 µM) for 48 hours. Three independent experiments were performed. 
Error bars represent mean ± s.e.m. ∗P < 0.05 ∗∗P < 0.01, by t-test analysis. Scale bars: 100 
μm. (C) Upper, images showing representative staining of BrdU positive cells from 
endometrial epithelial 3D cultures treated (PTEN KO) or not (PTEN WT) with tamoxifen 
to induce PTEN deletion and in combination or not with Palbociclib at 2.5, 5 and 10 µM 
doses. Bottom, quantification of the number of BrdU positive cells from the same cultures. 
Nuclei were evidenced by Hoechst staining. Scale bar: 50 µm. Data are from n=3 
experimental replicates and values are mean ± s.e.m. ∗P < 0.05 ∗∗P < 0.01∗∗∗ P < 0.001, 
by t-test analysis.  
Supplementary Figure 6. Palbociclib effects on PTEN deficient thyroid hyperplasias. 
(A) Schematic representation of the protocol used for Palbociclib administration. (B) 
Macroscopic images and weight of thyroids from Palbociclib treated mice. ∗∗∗P< 0.001, by 
t-test analysis. (C) Representative images of HE staining (10x) and evaluation of thyroid 
lesions. No significant differences were observed by Chi square analysis. (D) 
29 
 
Representative images and quantification of Ki-67 immunostaining performed on thyroids 
dissected from mice treated or not with Palbociclib. Data are from n=5 for each genotype 
and values are mean ± s.e.m. ∗P < 0.05, by t-test analysis.   
Supplementary Figure 7. Palbociclib effects on PTEN deficient prostate neoplasias. 
(A) Schematic representation of the protocol used for Palbociclib administration. (B) 
Macroscopic images and weight of prostates from Palbociclib treated mice. ∗∗∗P< 0.001, 
by t-test analysis. (C) Representative images of HE staining (10x) and evaluation of 
prostate lesions. No significant differences were observed by Chi square analysis. hgPIN 
means high-grade PIN. (D) Representative images and quantification of Ki-67 
immunostaining performed on prostates dissected from mice treated or not with 
Palbociclib. Data are from n=5 for each genotype and values are mean ± s.e.m. ∗∗P < 0.01, 
by t-test analysis.  
Supplementary Figure 8. p-Rb IHC Quantification and western blot analysis. (A) 
Quantification, by automated ACIS III system, of p-Rb IHC performed on endometrium 
after short-course treatment with Palbociclib. Data are from n=3 for each group and values 
are mean ± s.e.m. ∗∗P < 0.01, by t-test analysis. (B,C and D) IHC quantification results of 
p-Rb (Ser780) on endometrium (B), thyroid (C) and prostate (D) dissected from animals 
Cre:ERT+/- PTENf/f treated with vehicle or Palbociclib for 21 consecutive days. Data are 
from n=6 for each group and values are mean ± s.e.m. no significant differences were 
observed by t-test analysis. (E) Evaluation of p-S6K, p-AKT, Total AKT, p-ERK, pan-
ERK, Cyclin D1, CDK2, Cyclin E, p27 and p-Rb expression by western blot in uterus 
collected from Cre:ERT+/- PTENfl/fl treated with Palbociclib for 21 days. n=5 biological 
replicates is shown. Tubulin serves as loading control. 
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Supplementary Figure 9. Palbociclib treatment exhibits an anti-proliferative effect in 
vitro on human endometrial carcinoma cell lines. (A) HEC-1A and MFE-296 cells were 
treated with 2.5, 5 and 10 µM Palbociclib for 48h and cell viability was evaluated by MTT. 
Three independent experiments were performed. Results are expressed as percentage of 
survival over control values. ∗P < 0.05 ∗∗P < 0.01 ∗∗∗P < 0.001, by two-way ANOVA, 
followed by the Bonferroni post hoc comparison test. (B) After 48 hours treatment of HEC-
1A and MFE-296 endometrial carcinoma cell lines with 5 µM and 10 µM Palbociclib, 
propidium iodide staining was performed to evaluate DNA content by flow cytometry. Data 
are from n=3 experimental replicates. ∗∗P < 0.01 ∗∗∗P < 0.001, by one-way ANOVA, 
followed by the Tukey’s multiple comparison test. (C) HEC-1A three-dimensional cultures 
were treated for 48 hours with 5 µM and 10 µM Palbociclib and spheroid diameter was 
evaluated. Three independent experiments were performed. ∗∗∗P < 0.001, by one-way 
ANOVA, followed by the Tukey’s multiple comparison test. 
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